A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

PURPOSE: Clostridium difficile infection (CDI) represents a significant economic healthcare burden, especially the cost of recurrent disease. Fidaxomicin produced significantly lower recurrence rates and higher sustained cure rates in clinical trials. We evaluated the cost-effectiveness and budget i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Infection
Main Authors: Watt, Maureen, McCrea, Charles, Johal, Sukhvinder, Posnett, John, Nazir, Jameel
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2016
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5042976/
https://ncbi.nlm.nih.gov/pubmed/27062378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s15010-016-0894-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados